FDA Approves At-Home Starting Dose of Lecanemab for Treatment of Alzheimer Disease

The FDA approved a new starting dosage regimen for the subcutaneous formulation of lecanemab-irmb (Leqembi; Eisai, Biogen), marking the first time patients can begin treatment with home administration either by themselves or by their caregiver.¹

Lecanemab is an amyloid beta-directed antibody that targets and removes beta-amyloid from the brain. There is no evidence that lecanemab restores or reverses lost memories or cognitive function, but it is proven to reduce both cognitive and functional decline in patients, according to the Alzheimer’s Association. Previously, the agent received FDA approval for the treatment of early Alzheimer disease, including those with mild cognitive impairment or mild dementia due to Alzheimer disease who have confirmation of elevated beta-amyloid in the brain, and in January 2025, the FDA approved maintenance dosing of lecanemab once every 4 weeks for early Alzheimer disease.^2,3

Data from 2 clinical trials (Study 1: NCT01767311; Study 2: NCT03887455)^4,5 supported the approval of lecanemab. Both trials were randomized, placebo-controlled studies, and enrolled patients were randomly assigned to receive either lecanemab or a placebo (an inactive treatment), and neither the patients nor the researchers knew who received which treatment during the study.^4,5

The studies evaluated the efficacy, safety, pharmacokinetics, and long-term effects of lecanemab in participants with early Alzheimer. The primary efficacy end points included change from baseline in the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at 18 months during the core study and continued assessment through up to 66 months in the extension phase. Secondary outcomes assessed changes in amyloid burden using PET imaging (Centiloids), cognition and function using ADAS-Cog14, ADCOMS, and ADCS MCI-ADL; as well as biomarkers, brain volume, and hippocampal volume. Safety was evaluated by monitoring treatment-emergent adverse events (AEs), serious AEs, laboratory assessments, MRI, electrocardiograms, and other clinical measures throughout both the core and extension phases, and additional analyses characterized serum pharmacokinetics and long-term exposure to lecanemab.^4,5

Study 1 enrolled 854 participants (lecanemab: n = 609; placebo: n = 245) and found that, although the primary 12-month end point was not met, treatment with lecanemab demonstrated clinically meaningful benefits by 18 months. Compared with placebo, lecanemab significantly reduced brain amyloid burden (–0.306 SUVr units) and slowed cognitive and functional decline across multiple measures, including ADCOMS, ADAS-Cog14, and CDR-SB, with cerebrospinal fluid biomarkers supporting a treatment effect. Lecanemab was generally well tolerated, with amyloid-related imaging abnormalities with edema/effusion (ARIA-E) occurring in approximately 9.9% of participants receiving the 10-mg/kg biweekly dose.⁶

Study 2, or Clarity AD, enrolled 1795 participants and met its primary end point, demonstrating significantly less clinical decline with lecanemab than placebo on CDR-SB at 18 months, along with greater reductions in brain amyloid burden and significant improvements across ADAS-Cog14 (−1.44 [95% CI, −2.27 to −0.61]; P < .001), ADCOMS (−0.050 [95% CI, −0.074 to −0.027]; P < .001), and ADCS-MCI-ADL (2.0 [95% CI, 1.2 to 2.8]; P < .001). The most common AEs included infusion-related reactions (26.4%) and ARIA-E (12.6%).⁷

The FDA notes that lecanemab is contraindicated in patients with serious hypersensitivity to lecanemab or to any of its inactive ingredients. Additionally, the prescribing information recommends caution when considering the use of lecanemab in patients taking anticoagulants or with other risk factors for intracerebral hemorrhage.¹

REFERENCES

1. FDA Approves First At-home Starting Dose for Alzheimer’s Disease Treatment. FDA. News release. July 12, 2026. Accessed July 13, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment

2. McGovern G. FDA Approves Subcutaneous Lecanemab Injection for Maintenance Dosing in Early Alzheimer Disease. Pharmacy Times. September 2, 2025. Accessed July 13, 2026. https://www.pharmacytimes.com/view/fda-approves-subcutaneous-lecanemab-injection-for-maintenance-dosing-in-early-alzheimer-disease

3. Halpern L. FDA Approves Lecanemab-Irmb Maintenance Dosing for Early Alzheimer Disease Treatment. Pharmacy Times. Updated January 27, 2025. Accessed July 13, 2026. https://www.pharmacytimes.com/view/fda-approves-lecanemab-irmb-maintenance-dosing-for-early-alzheimer-disease-treatment

4. A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease. ClinicalTrials.gov identifier: NCT01767311. Updated March 4, 2026. Accessed July 13, 2026. https://clinicaltrials.gov/study/NCT01767311

5. A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD). ClinicalTrials.gov identifier: NCT03887455. Updated April 7, 2026. Accessed July 13, 2026. https://clinicaltrials.gov/study/NCT03887455

6. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13(1):80. doi:10.1186/s13195-021-00813-8

7. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948